Alpha DaRT plus pembrolizumab produced responses in all evaluable elderly patients with PD-L1–positive recurrent/metastatic head and neck cancer.
Feature|Articles|May 26, 2026
Novel Proton Therapy Techniques and EGFR-Directed Agents Drive the Future of Head and Neck Cancer Care
Author(s)Ashling Wahner
Fact checked by: Riley Kandel, Afton Woodward
Bispecific antibodies and the latest proton therapy techniques are taking center stage in the treatment of patients with head and neck cancers.
Advertisement
Advertisement
Innovative targeted agents and specified proton therapy applications are among the most promising evolving strategies for head and neck cancer management, providing a foundation for future patient care that is highly individualized and provides enduring treatment options for patients who have received prior lines of therapy.
Related to this article
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
Advertisement
Advertisement